Jeffrey A. Meckler Sells 40,000 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) Director Jeffrey A. Meckler sold 40,000 shares of Travere Therapeutics stock in a transaction on Monday, September 30th. The stock was sold at an average price of $14.06, for a total value of $562,400.00. Following the completion of the transaction, the director now owns 81,000 shares in the company, valued at $1,138,860. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Travere Therapeutics Stock Down 0.1 %

Shares of NASDAQ:TVTX traded down $0.02 on Monday, reaching $13.99. The company had a trading volume of 1,977,019 shares, compared to its average volume of 1,318,661. The company has a quick ratio of 2.99, a current ratio of 3.04 and a debt-to-equity ratio of 24.96. The stock has a market capitalization of $1.07 billion, a P/E ratio of -6.60 and a beta of 0.71. The stock has a 50-day moving average price of $10.66 and a 200 day moving average price of $8.45. Travere Therapeutics, Inc. has a twelve month low of $5.12 and a twelve month high of $15.36.

Travere Therapeutics (NASDAQ:TVTX) last announced its earnings results on Thursday, August 1st. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.03). The company had revenue of $54.12 million for the quarter, compared to the consensus estimate of $49.50 million. Travere Therapeutics had a negative return on equity of 269.18% and a negative net margin of 82.14%. On average, equities analysts expect that Travere Therapeutics, Inc. will post -3.95 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have issued reports on TVTX. Citigroup cut their price objective on Travere Therapeutics from $23.00 to $19.00 and set a “buy” rating on the stock in a report on Friday. Guggenheim cut their price target on shares of Travere Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a report on Friday. Barclays raised their price objective on shares of Travere Therapeutics from $12.00 to $14.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Bank of America cut their target price on shares of Travere Therapeutics from $19.00 to $18.00 and set a “buy” rating on the stock in a research note on Friday. Finally, HC Wainwright decreased their target price on Travere Therapeutics from $23.00 to $18.00 and set a “buy” rating for the company in a research report on Friday. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $16.73.

Institutional Investors Weigh In On Travere Therapeutics

A number of hedge funds have recently bought and sold shares of TVTX. Assenagon Asset Management S.A. boosted its stake in Travere Therapeutics by 912.5% during the 2nd quarter. Assenagon Asset Management S.A. now owns 2,214,099 shares of the company’s stock valued at $18,200,000 after purchasing an additional 1,995,419 shares during the period. Parkman Healthcare Partners LLC grew its stake in shares of Travere Therapeutics by 76.4% in the fourth quarter. Parkman Healthcare Partners LLC now owns 1,018,812 shares of the company’s stock worth $9,159,000 after acquiring an additional 441,318 shares during the last quarter. Russell Investments Group Ltd. increased its position in Travere Therapeutics by 79.2% during the first quarter. Russell Investments Group Ltd. now owns 184,623 shares of the company’s stock worth $1,423,000 after acquiring an additional 81,611 shares during the period. GSA Capital Partners LLP acquired a new position in Travere Therapeutics during the 1st quarter valued at $452,000. Finally, Healthcare of Ontario Pension Plan Trust Fund bought a new stake in Travere Therapeutics in the 4th quarter valued at $5,711,000.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.